Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.31 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.31 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046172 | 0.85 | ALDH1A1 (0.46) | CA2CA12CA9CA3CA4 | |
| SCHEMBL3050989 | 0.82 | KDM5A (0.32) | — | |
| SCHEMBL3760709 | 0.80 | CA12 (0.37) | CA2CA12CA9CA3CA4 | |
| SCHEMBL1120257 | 0.79 | — | — | |
| SCHEMBL6656657 | 0.79 | — | — | |
| SCHEMBL3724851 | 0.78 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL9613685 | 0.77 | CA12 (0.48) | CA2CA12CA9CA3CA4 | |
| SCHEMBL3052224 | 0.77 | — | — | |
| SCHEMBL3718113 | 0.77 | — | — | |
| SCHEMBL3050456 | 0.77 | MEN1 (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010131-A1 | NOVEL CYCLOSPORIN ANALOGUES | SCYNEXIS, INC. (US) | 2012-01-12 | — | — | US | claimed |
| WO-2011082289-A1 | CYCLOSPORINE ANALOGUES | SCYNEXIS INC. (US) | 2011-07-07 | — | — | WO | claimed |
| EP-2280989-A2 | CYCLOSPORIN ANALOGS AND THEIR USE IN THE TREATMENT OF HCV INFECTIONS | Scynexis, Inc. (US) | 2011-02-09 | — | — | EP | claimed |
| WO-2010138423-A1 | CYCLOSPORIN DERIVATIVES FOR TREATING INFLAMMATORY DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305037-A1 | CYCLOSPORIN DERIVATIVES FOR TREATING INFLAMMATORY DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2010-12-02 | — | — | US | claimed |
| EP-0948527-B1 | CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2002-06-05 | — | — | EP | claimed |
| EP-0951474-B1 | NOVEL CYCLOSPORIN DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2002-06-05 | — | — | EP | claimed |
| CN-116963780-A | Compositions and methods for cardiomyocyte transplantation | 华盛顿大学 | 2023-10-27 | — | — | CN | disclosed |
| EP-2280989-B1 | CYCLOSPORIN ANALOGS AND THEIR USE IN THE TREATMENT OF HCV INFECTIONS | SCYNEXIS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9090671-B2 | Macrocyclic peptides | SCYNEXIS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140005124-A1 | CYCLOSPORIN DERIVATIVES FOR TREATING INFLAMMATORY DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8524671-B2 | Cyclosporin derivatives for treating inflammatory diseases and conditions | ALLERGAN, INC (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2519538-A1 | CYCLOSPORINE ANALOGUES | Scynexis, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2001-09-27 | — | — | US | disclosed |
| EP-1098903-A1 | NOVEL METHOD FOR PREPARING CYCLOSPORIN DERIVATIVES | Aventis Pharma S.A. (FR) | 2001-05-16 | — | — | EP | disclosed |
| EP-1040121-A1 | NOVEL METHOD FOR PREPARING CYLOSPORIN DERIVATIVES | Aventis Pharma (FR) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999067280-A1 | NOVEL METHOD FOR PREPARING CYCLOSPORIN DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 1999-12-29 | — | — | WO | disclosed |
| EP-0951474-A1 | NOVEL CYCLOSPORIN DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-27 | — | — | EP | disclosed |
| WO-1999032512-A1 | NOVEL METHOD FOR PREPARING CYLOSPORIN DERIVATIVES | AVENTIS PHARMA (FR) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998028330-A1 | NOVEL CYCLOSPORIN DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305037-A1 | CYCLOSPORIN DERIVATIVES FOR TREATING INFLAMMATORY DISEASES AND CONDITIONS | MALT1, UACA, CD40 | CA2 728/4885CA12 2319/4885CA9 1744/4885 |
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | MGMT, MALT1, TET2 | CA2 804/4885CA12 650/4885CA9 1734/4885 |
| US-20120010131-A1 | NOVEL CYCLOSPORIN ANALOGUES | PPP3R1, FKBP1B, FKBP1A | CA2 3520/4885CA12 2498/4885CA9 3451/4885 |
| US-20140005124-A1 | CYCLOSPORIN DERIVATIVES FOR TREATING INFLAMMATORY DISEASES AND CONDITIONS | MALT1, UACA, CD40 | CA2 728/4885CA12 2319/4885CA9 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.